Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

PMV stock hub: rezatapopt ovarian responses, Q4 2026 data, Q1 2027 NDA plan, cash runway, September financing, warrant reset and dated short interest.

PMV Pharmaceuticals ($PMVP) stock hub: rezatapopt pivotal PYNNACLE ovarian data at 46% ORR on 76 patients, the September 2026 financing and its resettable warrants, and the accelerated-approval NDA guided for Q1 2027.

Click to view the official SEC document.

PMV Pharma (Nasdaq: PMVP) priced an oversubscribed underwritten public offering totaling approximately $50.8 million in gross proceeds. The deal includes 22,055,000 shares of common stock, pre-funded warrants to purchase up to 19,900,000 shares, and accompanying warrants to purchase an aggregate of 41,955,000 shares.Each share of common stock plus accompanying warrant is priced at $1.21, while each pre-funded warrant plus accompanying warrant is priced at $1.20999. The accompanying warrants are immediately exercisable at an initial exercise price of $1.21 per share, subject to adjustment after a specified regulatory milestone, and will expire five years from issuance. All securities are being sold by PMV Pharma, with TD Cowen as sole book-running manager. Closing is expected on or about September 2, 2026, subject to customary conditions.

Click to view the official SEC document.

PMV Pharma (Nasdaq: PMVP) has commenced an underwritten public offering of its common stock with accompanying warrants, and pre-funded warrants with accompanying warrants for certain investors. All securities in the proposed offering will be sold by PMV Pharma. TD Cowen is the sole book-running manager, and the transaction is being conducted under an effective shelf registration statement on Form S-3. Completion, timing, size and final terms of the offering remain subject to market and other conditions.

PMV Pharmaceuticals (Nasdaq: PMVP) reported updated interim ovarian cancer data from the Phase 2 pivotal portion of its PYNNACLE trial of rezatapopt monotherapy (2000 mg once-daily) in patients with TP53 Y220C advanced solid tumors. As of the May 14, 2026 cutoff, the efficacy population included 76 platinum-resistant/refractory ovarian cancer patients with at least one post-baseline tumor assessment or early discontinuation.According to PMV Pharma, the ovarian cancer cohort showed an overall response rate (ORR) of 46% (35/76), including four confirmed complete responses, 29 confirmed partial responses, and two unconfirmed partial responses, per investigator RECIST v1.1 assessment. Median time to response was 1.3 months, and median duration of response was 10.0 months based on confirmed responses. Rezatapopt’s safety profile remained favorable, with mostly Grade 1–2 treatment-related adverse events and a 5% discontinuation rate due to treatment-related adverse events; safety in the ovarian cohort was similar to the overall population. PMV Pharma completed enrollment of the ovarian cancer cohort for the primary analysis and plans a broader PYNNACLE update, including primary analysis data, at a medical conference in fourth-quarter 2026. Following recent FDA feedback supporting its strategy, the company anticipates submitting a New Drug Application for accelerated approval in platinum-resistant/refractory TP53 Y220C ovarian cancer in the first quarter of 2027.

PMV Pharmaceuticals (Nasdaq: PMVP) reported second quarter 2026 results and clinical progress for rezatapopt. Enrollment for the primary analysis in the Phase 2 monotherapy portion of the registrational PYNNACLE trial in platinum-resistant/refractory ovarian cancer has been completed. The company plans to submit a rezatapopt NDA for accelerated approval in this indication in the first quarter of 2027.PMV Pharma reported $79.4 million in cash, cash equivalents and marketable securities as of June 30, 2026, and expects this to fund operations through the second quarter of 2027. Net loss for the quarter was $18.1 million, down from $21.2 million a year earlier, with R&D expenses reduced to $14.7 million from $18.4 million and G&A expenses down to $4.2 million from $4.5 million. Net cash used in operations for the first half of 2026 was $34.3 million versus $36.6 million in the prior-year period.

Click to view the official SEC document.

The grant will help fund the consortium’s work in improving tech infrastructure and creating more sustainable business models for local public media

YouTube video by Ruki Otokado 音門るき [VEE]

YouTube video by Ruki Otokado 音門るき [VEE]